semaglutide retatrutide Acute and chronic effects of retatrutide, and long‐acting Retatrutide vs Semaglutide: Triple Agonist

Orforglipron is the active ingredient

No phase 1, phase 2, or phase 3 clinical trials have been conducted

Ingredients Water, ethylhexyl palmitate, squalane, stearic acid, Copper Tripeptide-1 (GHK-Cu), methylsulfonylmethane, dimethyl MEA (DMAE), cetyl alcohol, glyceryl stearate, PEG-100 stearate, nannochloropsis oculata extract (with pullulan, aqua, phenoxyethanol, and sodium benzoate potassium sorbate), PPG 2 myristyl ether propionate, phenoxyethanol, C10-30 cholesterol/lanosterol esters, polysorbate 80, allantoin, leucine, lavandula angustifolia (lavender) oil, aloe barbadensis (aloe vera) powder, sodium salicylate, vitamin E TPGS (tocophersolan), vitamin E (as d-alpha tocopherol plus mixed tocopherols: d-beta, d-delta and d-gamma tocopherol)

Patent Nos

6 Limitation and future research priorities Despite the promising potential of ferroptosis-targeting therapies, several limitations currently hinder their translation into clinical practice